Vanta Bioscience Ltd
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]
- Market Cap ₹ 16.5 Cr.
- Current Price ₹ 23.2
- High / Low ₹ 31.3 / 14.7
- Stock P/E
- Book Value ₹ 27.1
- Dividend Yield 0.00 %
- ROCE -11.6 %
- ROE -37.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.86 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -32.3% over past five years.
- Company has a low return on equity of -27.2% over last 3 years.
- Company has high debtors of 466 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 12.08 | 13.75 | 9.82 | 9.40 | 5.83 | 9.72 | 1.96 | 1.23 | |
| 8.81 | 9.38 | 5.87 | 5.93 | 8.22 | 8.41 | 6.21 | 5.48 | |
| Operating Profit | 3.27 | 4.37 | 3.95 | 3.47 | -2.39 | 1.31 | -4.25 | -4.25 |
| OPM % | 27.07% | 31.78% | 40.22% | 36.91% | -40.99% | 13.48% | -216.84% | -345.53% |
| 0.23 | 0.11 | 0.03 | 0.42 | 0.69 | 0.11 | 0.11 | 0.07 | |
| Interest | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | 4.07 | 2.80 |
| Depreciation | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | 4.42 | 3.34 |
| Profit before tax | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | -12.63 | -10.32 |
| Tax % | 36.36% | 24.63% | 23.73% | 40.91% | 1.75% | -2.49% | 5.23% | |
| 0.70 | 1.01 | 0.45 | 0.14 | -10.44 | -8.61 | -13.29 | -4.53 | |
| EPS in Rs | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 | -3.68 | -7.56 | -6.85 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -41% |
| TTM: | -73% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -33% |
| 3 Years: | -21% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -27% |
| Last Year: | -37% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 7.11 |
| Reserves | 15.94 | 17.16 | 17.61 | 17.70 | 11.20 | 8.89 | 4.11 | 12.14 |
| 13.25 | 17.37 | 35.97 | 44.86 | 57.16 | 60.96 | 70.09 | 30.57 | |
| 3.51 | 7.74 | 9.74 | 12.53 | 10.04 | 9.24 | 5.37 | 7.04 | |
| Total Liabilities | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 56.86 |
| 17.90 | 20.76 | 29.39 | 36.12 | 57.22 | 54.15 | 55.50 | 41.82 | |
| CWIP | 3.70 | 7.00 | 19.34 | 28.47 | 10.60 | 12.53 | 13.47 | 0.00 |
| Investments | 1.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 |
| 15.46 | 20.82 | 20.90 | 16.81 | 16.89 | 18.72 | 16.91 | 12.04 | |
| Total Assets | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 56.86 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -1.04 | 2.34 | 6.97 | 5.28 | -0.63 | 2.68 | -2.41 | |
| -5.73 | -7.59 | -22.30 | -17.24 | -5.91 | -3.31 | -6.69 | |
| 9.94 | 2.17 | 17.78 | 9.53 | 6.41 | 0.69 | 9.16 | |
| Net Cash Flow | 3.18 | -3.07 | 2.46 | -2.43 | -0.13 | 0.06 | 0.06 |
| Free Cash Flow | -3.52 | -5.01 | -15.23 | -11.90 | -6.54 | -0.63 | -9.10 |
| CFO/OP | -32% | 54% | 176% | 152% | 26% | 205% | 57% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 465.56 |
| Inventory Days | 2,400.15 | ||||||
| Days Payable | 1,821.31 | ||||||
| Cash Conversion Cycle | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 1,044.40 |
| Working Capital Days | 260.76 | 259.61 | 91.06 | -135.13 | -163.40 | -217.42 | -2,126.68 |
| ROCE % | 8.35% | 5.21% | 3.77% | -5.82% | -4.16% | -11.58% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Research & Development (R&D) Expenditure INR Lakhs ・Standalone data |
|
||||||||
| Total Headcount (Permanent Employees) Number ・Standalone data |
|||||||||
| Unbilled Revenue (Services Under Process/Inventory) INR Lakhs ・Standalone data |
|||||||||
| Number of Scientists Number ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Audited Standalone And Consolidated Financial Results For The Half Year And Financial Year Ended March 31, 2026
1d - Board approved FY26 audited results and reappointed MD Dopesh Raja Mulakala for three years from April 18, 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 30.05.2026
1d - Board approved FY26 audited standalone and consolidated results; reappointed MD for three years from April 18, 2026.
-
Board Meeting Intimation for Approval Of Standalone And Consolidated Audited Financial Results For The Half Year And Financial Year Ended March 31, 2026 - Board Meeting To Be Held On May 30, 2026
26 May - Board meets May 30, 2026 to approve audited results for half year and FY ended March 31, 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Apr
- Closure of Trading Window 24 Mar
Business Overview:[1][2][3]
a) VBSL conducts R&D, clinical, and pre-clinical studies across genetic, animal, inhalation, and eco-toxicology.
b) It is a preclinical contract research company offering safety assessment services to clients in pharma, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemicals.
c) The company provides risk assessment services for APIs, excipients, extractables, leachables, and impurities arising from manufacturing or product degradation.
d) VBSL also offers expert services to determine health-based exposure limits, including PDE, ADE, and OEL for pharmaceutical manufacturers.